

Application No. 10/088,354
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (Cancelled)

11. (Currently amended) A compound of formula (IIB)



(IIB)

or a salt, ester, amide or prodrug thereof

where

X is O, or S, S(O) or S(O)₂, NH or NR⁸ where R⁸ is hydrogen or C₁₋₆alkyl,

Z is O or S,

R⁹ is hydrogen or optionally substituted hydrocarbyl or optionally substituted heterocyclyl ethenyl, optionally substituted phenyl, optionally substituted pyridyl or optionally substituted furanyl where optional substituents for R⁹ groups are C₁₋₃alkoxy, C₁₋₃alkyl, halo or nitro,

R⁶ and R⁷ are independently selected from hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkoxy,

C₁₋₄alkoxymethyl, di(C₁₋₄alkoxy)methyl, C₁₋₄alkanoyl, trifluoromethyl, cyano, amino, C₂₋₆alkenyl,

C₂₋₆alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3

heteroatoms, selected independently from O, S and N, which heterocyclic group may be

aromatic or non-aromatic and may be saturated and and [[D]]linked via a ring carbon or nitrogen

atom^{[[D]]} or unsaturated and and [[I]]linked via a ring carbon atom^{[[D]]}, and which phenyl, benzyl or

heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected

from hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino,

nitro, C₂₋₄alkanoyl, C₁₋₄alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphinyl,

C₁₋₄alkylsulphonyl, carbamoyl, N-C₁₋₄alkylcarbamoyl, N,N-di(C₁₋₄alkyl)carbamoyl,

Application No. 10/088,354
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005

aminosulphonyl, N-C₁₋₄alkylaminosulphonyl, N,N-di(C₁₋₄alkyl)aminosulphonyl, C₁₋₄alkylsulphonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkoxyloxy, trifluoromethyl, cyano, amino, nitro and C₁₋₄alkoxycarbonyl, R¹ is hydrogen, R⁴ is hydrogen, halo, C₁₋₄alkyl or C₁₋₄alkoxy are independently selected from halogeno, cyano, nitro, C₁₋₃alkylsulphonyl, N(OH)R¹² (wherein R¹² is hydrogen, or C₁₋₃alkyl), or R¹⁴X¹ (wherein X¹ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR¹⁵C(O)-, -C(O)NR¹⁶-, -SO₂NR¹⁷-, -NR¹⁸SO₂- or -NR¹⁹ (wherein R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl)), and R¹⁴ is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy


and n is 0, or an integer of from 1 to 6,

R^{8a} is halo, cyano, nitro, trifluoromethyl, C₁₋₃alkyl, -NR¹²R¹³ [(wherein R¹² and R¹³, which may be the same or different, each represents hydrogen or C₁₋₃alkyl)]], or a group -X¹R¹⁴ [(wherein X¹ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR¹⁵C(O)-, -C(O)NR¹⁶-, -SO₂NR¹⁷-, -NR¹⁸SO₂- or -NR¹⁹ [(wherein R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl)]], and R¹⁴ is hydrogen or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, oxiranyl, fluoro, chloro, bromo and amino including C₁₋₃alkyl and trifluoromethyl; or -R⁹R³⁸ and wherein R³⁸ represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group linked via carbon or nitrogen with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, nitro, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₃alkylamino, C₁₋₄hydroxyalkoxy, oxo, cyano, C₁₋₄alkyl, cyclopropyl, C₁₋₄alkylsulphonyl, C₁₋₄alkyl, C₁₋₄alkoxycarbonyl, di(C₁₋₄alkyl)amino, C₁₋₄alkylamino, C₁₋₄alkyl, di(C₁₋₄alkyl)amino, C₁₋₄alkylamino, C₁₋₄alkoxy, di(C₁₋₄alkyl)amino, C₁₋₄alkoxy, carboxy, carboxamido, trifluoromethyl, cyano, -C(O)NR³⁹R⁴⁰, -NR⁴¹C(O)R⁴² wherein R³⁹, R⁴⁰, R⁴¹ and R⁴², which may be the same or different, each represents hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl and a group -(-O-)_f(C₁₋₄alkyl)_gringD wherein f is 0 or 1, g is 0 or 1 and ring D is a cyclic group selected from C₃₋₆cycloalkyl, aryl or 5-6-membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C₁₋₄alkyl; and wherein R⁹ is a C₁₋₈alkylene group optionally

Application No. 10/088,354
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005

substituted by one or more substituents selected from hydroxy, halogeno and amino hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy;

and R^{67} is C_{1-8} alkoxy optionally substituted with a group X^1R^{38} [([)] wherein X^1 represents a direct bond, O , CH_2 , $OC(O)$, $C(O)$, S , SO , SO_2 , $NR^{15}C(O)$, $C(O)NR^{16}$, SO_2NR^{17} , $NR^{18}SO_2$ or NR^{19} (wherein R^{15} , R^{16} , R^{17} , R^{18} and R^{19} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl)), and R^{38} are as defined above is a pyridone-group, an aryl-group or an aromatic heterocyclic-group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, aryl or aromatic heterocyclic-group may be substituted by one or more functional groups or by a hydrocarbyl-group optionally substituted by one or more functional groups; or heterocyclyl groups, or by a heterocyclyl-group optionally substituted by one or more functional groups or hydrocarbyl groups, or R^{67} is 3-morpholinopropoxy; provided that R^{67} is other than unsubstituted alkoxy; or a compound of formula (IIIb)



(IIIb)


or a salt, ester, amide or prodrug thereof,

where X , R^4 , R^5 and R^7 are as defined above, and R^{68} and R^{67} are as defined above provided that R^{67} is other than unsubstituted alkoxy; and R^6 is benzyl or cyanobenzyl or R^6 is optionally substituted phenyl, where the optional substituents include C_{1-3} alkyl groups as well as nitro and halo or R^6 is ethynyl optionally substituted with trimethylsilyl groups, carboxy, or an C_{1-8} alkyl ester thereof;

or

a compound of formula (IVb)

Application No. 10/088,354
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005




(IVB)

or a salt, ester, amide or prodrug thereof,

where X, R¹, R², R³ and R⁴ are as defined above, R⁵ is a group of formula NR¹⁰R^{10'} where R¹⁰ and R^{10'} are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R¹⁰ and R^{10'} together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which may optionally contain further heteroatoms, or an azo group of formula N=N-R¹¹ where R¹¹ is an optionally substituted hydrocarbyl group or optionally substituted heterocyclyl group, or R⁵ is a group -N=NR¹¹ where R¹¹ is as defined above, and R⁶ and R⁷ are as defined above provided that R⁷ is other than unsubstituted alkoxy;

or

a compound of formula (IVC)




(IVC)

or a salt, ester, amide or prodrug thereof,

where R¹, R², R³, R⁴ and X are as defined in claim 1.


Application No. 10/088,854
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005

12. (Currently amended) A method of preparing a compound according to claim 11, which comprises reacting a compound of formula (VII)







(VII)

where R^{1'}, R^{2''}, R^{3'}, and R^{4'} are respectively equivalent to a group R¹, R⁶⁶, R⁶⁷ and R⁴ as defined in claim 11 or a precursor thereof, and R⁸⁵ is a leaving group, with a compound of formula (VIII)



(VIII)

where X, is as defined in claim 11, and R^{8''} is selected from



where Z, n, R⁶, R⁷ and R⁹ are as defined in claim 11,

Application No. 10/088,854
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005

~~R⁶ is an optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy group, provided that R⁶ is other than ethenyl substituted by a carboxy group or an amide or sulphonamide derivative thereof,~~
~~and R^{6a} is halogen or a group of formula -NR¹⁰R^{10'} where R¹⁰ and R^{10'} are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R¹⁰ and R^{10'} together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which may optionally contain further heteroatoms, or an azo group of formula -N=N-R¹¹ where R¹¹ is an optionally substituted hydrocarbyl group or optionally substituted heterocyclyl group).~~

13-14. (Canceled)

15. (Currently Amended) A pharmaceutical composition comprising a compound of formula (IIB), (IIB), (IVB) or (IVC) as defined in claim 11, or a salt, ester, amide or prodrug thereof, in combination with a pharmaceutically acceptable carrier.

16. (Currently amended) A compound according to claim 11, ~~selected from:~~

~~a compound of formula (IIB) or a salt, ester, amide or prodrug thereof, wherein~~

~~wherein X is O, S, S(O) or S(O)₂, or -NR⁸ where R⁸ is hydrogen or C₁₋₆ alkyl;~~

~~Z is O or S,~~

~~n is 0, or an integer from 1 to 6,~~

~~R¹ and R⁴ are both hydrogen;~~

~~R⁹ is hydrogen, ethenyl, optionally substituted phenyl, optionally substituted pyridyl, or optionally substituted furanyl where optional substituents for R⁹ groups are C₁₋₃alkoxy, C₁₋₃alkyl, halo or nitro,~~

~~R⁸ and R⁷ are independently selected from hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkoxy,~~

~~C₁₋₄alkoxymethyl, di(C₁₋₄alkoxy)methyl, C₁₋₄alkanoyl, trifluoromethyl, cyano, amino, C₂₋₆alkenyl,~~

~~C₂₋₆alkynyl, a phenyl group, a benzyl group or a 5-6 membered heterocyclic group with 1-3~~

~~heteroatoms, selected independently from O, S and N, which heterocyclic group may be~~

~~aromatic or non-aromatic and may be saturated (linked via a ring carbon or nitrogen atom) or~~

~~unsaturated (linked via a ring carbon atom), and which phenyl, benzyl or heterocyclic group may~~

~~bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno,~~

~~C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C₂₋₄alkanoyl,~~

~~C₁₋₄alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphonyl, C₁₋₄alkylsulphinyl, C₁₋₄alkylsulphenyl,~~

Application No. 10/088,854
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005

carbamoyl, N-(C₁₋₄alkyl)carbamoyl, N,N-di(C₁₋₄alkyl)carbamoyl, aminosulphonyl, N-(C₁₋₄alkyl)aminosulphonyl, N,N-di(C₁₋₄alkyl)aminosulphonyl, C₁₋₄alkylsulphonylamine, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C₁₋₄alkoxycarbonyl;
 R⁶⁸ is halo, cyano, nitro, trifluoromethyl, C₁₋₃alkyl, NR¹²R¹³ (wherein R¹² and R¹³, which may be the same or different, each represent hydrogen or C₁₋₃alkyl), or a group -X¹R¹⁴ where X¹ represents a direct bond, O, CH₂, OC(O), C(O), S, SO, SO₂, NR¹⁵C(O), C(O)NR¹⁶, SO₂NR¹⁷, NR¹⁸SO₂ or NR¹⁹ (wherein R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ each independently represent hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹⁴ is a group (1) where group (1) is hydrogen or C₁₋₆alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, oxiranyl, fluoro, chloro, bromo and amino (including C₁₋₃alkyl and trifluoromethyl); or a group (10) where group (10) is -R⁸R³⁸ and wherein R³⁸ represents a pyridone group, a phenyl group or a 5-6 membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, nitro, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, oxo, cyano, C₁₋₄alkyl, cyclopropyl, C₁₋₄alkylsulphonyl, C₁₋₄alkyl, C₁₋₄alkoxycarbonyl, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, C₁₋₄alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy, carboxy, carboxamide, trifluoromethyl, cyano, C(O)NR³⁹R⁴⁰, NR⁴¹C(O)R⁴² (wherein R³⁹, R⁴⁰, R⁴¹ and R⁴², which may be the same or different, each represents hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and a group -(O)-(C₁₋₄alkyl)_fringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a cyclic group selected from C₂₋₆cycloalkyl, aryl or 5-6 membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C₁₋₄alkyl); and wherein R⁸ is a C₁₋₈alkylene group optionally substituted by one or more substituents selected from hydroxy, halogeno and amino;
 and R⁶⁷ is 3-morpholinepropoxy;
 or
 a compound of formula (IIIb) or a salt, ester, amide or prodrug thereof,
 wherein X, R¹, R⁴, R⁶, R⁷ and R⁶⁸ are as defined above

Application No. 10/088,854
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005

R^{67} is C_{1-6} alkoxy optionally substituted with fluorine or a group X^1R^{38} in which X^1 represents a direct bond, O , CH_2 , OCC , carbonyl, S , SO , SO_2 , $NR^{12}CO$, $CONR^{12}$, SO_2NR^{12} , $NR^{13}SO_2$ or NR^{14} (wherein R^{12} , R^{13} and R^{14} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and R^{38} represents a pyridone group, a phenyl group or a 5-6 membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} hydroxyalkyl, C_{1-4} aminoalkyl, C_{1-4} alkylamino, C_{1-4} hydroxyalkoxy, carboxy, trifluoromethyl, cyano, $CONR^{39}R^{40}$ and $NR^{41}COR^{42}$ (wherein R^{39} , R^{40} , R^{41} and R^{42} which may be the same or different, each represents hydrogen, C_{1-4} alkyl or C_{1-3} alkoxy C_{2-3} alkyl); wherein at least R^{67} is other than unsubstituted alkoxy;

and R^6 is benzyl and cyanobenzyl or R^6 is optionally substituted phenyl, where the optional substituents include C_{1-3} alkyl groups as well as nitro and halo or R^6 is ethynyl optionally substituted with trimethylsilyl groups, carboxy, or an C_{1-6} alkyl ester thereof

or

a compound of formula (IVB) or a salt, ester, amide or prodrug thereof,

where X , R^1 , R^4 , R^5 and R^7 are as defined in relation to formula (IIB) above

R^{51} a group of formula $NR^{10}R^{10'}$ where R^{10} and $R^{10'}$ are independently selected from hydrogen, alkyl or heterocyclyl, or R^{10} and $R^{10'}$ together with the nitrogen atom to which they are attached form a morpholine or tetrahydropyridyl or R^{51} is a group $N=NR^{11}$ where R^{11} is alkyl or phenyl or heterocyclyl

and R^{68} and R^{67} are as defined in relation to formula (IIB) above;

or

a compound of formula (IVC) or a salt, ester, amide or prodrug thereof,

where X , R^1 , R^4 are as defined in relation to formula (IIB) above

R^2 and R^3 are independently selected from, halo, cyano, nitro, trifluoromethyl,

C_{1-3} alkyl, NR^9R^{10} (wherein R^9 and R^{10} , which may be the same or different, each represents

hydrogen or C_{1-3} alkyl), or X^1R^{14} (wherein X^1 represents a direct bond, O , CH_2 , OCC ,

carbonyl, S , SO , SO_2 , $NR^{12}CO$, $CONR^{12}$, SO_2NR^{12} , $NR^{13}SO_2$ or NR^{14} (wherein R^{12} ,

R^{13} and R^{14} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl), and R^{14} is

selected from one of the following groups:

1) hydrogen or C_{1-6} alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro or amino;

Application No. 10/088,854
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005

- 2') C_{1-6} alkyl X^2COR^{20} (wherein X^2 represents O or NR^{21} (in which R^{20} represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and R^{21} represents C_{1-3} alkyl, $NR^{22}R^{23}$ or OR^{24} (wherein R^{22} , R^{23} and R^{24} which may be the same or different each represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl);
- 3') C_{1-6} alkyl X^3R^{25} (wherein X^3 represents O , S , SO , SO_2 , OCO , $NR^{26}CO$, $CONR^{27}$, SO_2NR^{28} , $NR^{29}SO_2$ or NR^{30} (wherein R^{26} , R^{27} , R^{28} , R^{29} and R^{30} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and R^{25} represents hydrogen, C_{1-3} alkyl, cyclopentyl, cyclohexyl or a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O , S and N , which C_{1-3} alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4} alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-4} alkyl, C_{1-4} hydroxyalkyl and C_{1-4} alkoxy);
- 4') C_{1-6} alkyl X^4C_{1-6} alkyl X^5R^{31} (wherein X^4 and X^5 which may be the same or different are each O , S , SO , SO_2 , $NR^{32}C$, $CONR^{33}$, SO_2NR^{34} , $NR^{35}SO_2$ or NR^{36} (wherein R^{32} , R^{33} , R^{34} , R^{35} and R^{36} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and R^{31} represents hydrogen or C_{1-3} alkyl);
- 5') R^{37} (wherein R^{37} is a 5-6 membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O , S and N , which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} alkoxy C_{1-4} alkyl and C_{1-4} alkylsulphenyl C_{1-4} alkyl);
- 6') C_{1-6} alkyl R^{37} (wherein R^{37} is as defined hereinbefore in (5'));
- 7') C_{2-6} alkenyl R^{37} (wherein R^{37} is as defined hereinbefore in (5'));
- 8') C_{2-6} alkynyl R^{37} (wherein R^{37} is as defined hereinbefore in (5'));
- 9') R^{38} (wherein R^{38} represents a pyridone group, a phenyl group or a 5-6 membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O , N and S , which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} hydroxyalkyl, C_{1-4} aminoalkyl, C_{1-4} alkylamino, C_{1-4} hydroxyalkoxy, carboxy, trifluoromethyl, cyano, $CONR^{39}R^{40}$ and $NR^{41}COR^{42}$ (wherein R^{39} , R^{40} , R^{41} and R^{42} which may be the same or different, each represents hydrogen, C_{1-4} alkyl or C_{1-3} alkoxy C_{2-3} alkyl);
- 10') C_{1-6} alkyl R^{38} (wherein R^{38} is as defined hereinbefore in (9'));
- 11') C_{2-6} alkenyl R^{38} (wherein R^{38} is as defined hereinbefore in (9'));
- 12') C_{2-6} alkynyl R^{38} (wherein R^{38} is as defined hereinbefore in (9'));

Application No. 10/088,854
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005

~~13') C₁₋₆alkylX⁶R³⁸ (wherein X⁶ represents O, S, SO, SO₂, NR⁴³CO, CONR⁴⁴, SO₂NR⁴⁶, NR⁴⁶SO₂ or NF⁴⁷ (wherein R⁴³, R⁴⁴, R⁴⁵, R⁴⁶ and R⁴⁷ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R³⁸ is as defined hereinbefore in (9'));~~
~~14') C₂₋₆alkenylX⁷R³⁸ (wherein X⁷ represents O, S, SO, SO₂, NR⁴⁸CO, CONR⁴⁹, SO₂NR⁵⁰, NR⁵⁰SO₂ or NF⁵² (wherein R⁴⁸, R⁴⁹, R⁵⁰, R⁵¹ and R⁵² each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R³⁸ is as defined hereinbefore in (9'));~~
~~15') C₂₋₆alkynylX⁸R³⁸ (wherein X⁸ represents O, S, SO, SO₂, NR⁵³CO, CONR⁵⁴, SO₂NR⁵⁶, NR⁵⁶SO₂ or NF⁵⁷ (wherein R⁵³, R⁵⁴, R⁵⁶, R⁵⁵ and R⁵⁷ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R³⁸ is as defined hereinbefore in (9'));~~
~~16') C₁₋₃alkylX⁹C₁₋₃alkylR³⁸ (wherein X⁹ represents O, S, SO, SO₂, NR⁵⁸CO, CONR⁵⁹, SO₂NR⁶⁰, NR⁶⁰SO₂ or NF⁶² (wherein R⁵⁸, R⁵⁹, R⁶⁰, R⁶¹ and R⁶² each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R³⁸ is as defined hereinbefore in (9'));~~
 and
~~17') C₁₋₃alkylX⁹C₁₋₃alkylR³⁷ (wherein X⁹ and R³⁷ are as defined hereinbefore in (5'))).~~

17. (new) A compound according to claim 11 wherein R⁶⁷ is 3-morpholinopropoxy.
18. (new) A compound according to claim 11 wherein R⁸ and R⁷ are independently selected from hydrogen, halo, C₁₋₄alkoxy, cyano, trifluoromethyl or phenyl.
19. (new) A compound according to claim 11 wherein R⁶ and R⁷ are both hydrogen.
20. (new) A compound according to claim 11 wherein the prodrug is a phosphate or sulphate or an alkyl, aryl or aralkyl derivative thereof.
21. (new) A method of treating colorectal or breast cancer in a warm blooded animal comprising administering to said animal an effective amount of a compound according to claim 11 or a salt or prodrug thereof.